- Student Records
Programme & Unit Catalogues


PA20321: Specialised integrated unit 4: management of cardiovascular disease & endocrine disorders

[Page last updated: 15 October 2020]

Follow this link for further information on academic years Academic Year: 2020/1
Further information on owning departmentsOwning Department/School: Department of Pharmacy & Pharmacology
Further information on credits Credits: 12      [equivalent to 24 CATS credits]
Further information on notional study hours Notional Study Hours: 240
Further information on unit levels Level: Intermediate (FHEQ level 5)
Further information on teaching periods Period:
Semester 2
Further information on unit assessment Assessment Summary: CW 30%, EX 70%
Further information on unit assessment Assessment Detail:
  • Practical Report (CW 10% - Qualifying Mark: 40)
  • Problem Based Learning (CW 10% - Qualifying Mark: 40)
  • Mini MOT (CW 10% - Qualifying Mark: 40)
  • Exam (EX 70% - Qualifying Mark: 40)
Further information on supplementary assessment Supplementary Assessment:
Like-for-like reassessment (where allowed by programme regulations)
Further information on requisites Requisites: While taking this module you must take PA20318 AND take PA20319 AND take PA20320 AND take PA20322
Description: Aims:
To provide a comprehensive, integrated understanding of the design and development of medicines, their pharmacological actions in the body and the evidence-based approach to treatment of patients with the aim of promoting safe and effective outcomes in cardiovascular and major endocrine disorders.

Learning Outcomes:
After successfully completing this unit, the student pharmacist will be able to:
1. Describe the aetiology, epidemiology, pathophysiology and clinical symptoms of CV and major endocrine diseases and how they are diagnosed and treated.
2. Identify and utilise evidence-based approaches for the management of cardiovascular and major endocrine disorders.
3. Carry out and write-up an analytical mini-project
4. Explain how disease and patient factors affect drug therapy and determine therapy outcomes.
5. Evaluate the evidence base for the management of cardiovascular disease and major endocrine disorders
6. Describe the role of the pharmacist in prescribing, administering and monitoring medication for patients with cardiovascular and major endocrine disorders.
7. Use risk calculators and be able to make a referral based on a pharmacy-based cardiovascular risk assessment.
8. Reflect on their own practice in supporting patients with these diseases and identify areas for continuous improvement.
9. Make appropriate clinical decisions in support of patients with cardiovascular and major endocrine disorders.
10. Apply structured consultation skills to the conditions studied in this unit.

Skills:
Scientific and practical skills (T/F/A)
Study skills, handling information, working with others (T/F)
Problem solving (T/F/A)
Study skills (T/F)
Handling information (T/F/A)
Written communication (T/F/A)
Scientific & practical skills (T/F/A)
Information & communication technology (ICT) (T/F)

Content:
Content to include:
Clinical introduction and overview of therapeutic area - Problem-based learning case
* Pharmaceutics theme
- Peptide & protein delivery, recombinant technologies, insulin production
- Multiple dose pharmacokinetics and drug monitoring.
* Pharmacology theme
- Autonomic nervous system pharmacology
- Receptor signalling
- Regulation of blood pressure
- The kidney and diuretics
- Atherosclerosis and lipid lowering drugs
- Coagulation, anti-platelets and anticoagulants, DVT and pulmonary embolism
- Positive inotropes
* Medicinal chemistry and drug design theme
- Drug design and molecular modelling of drugs to treat cardiovascular disease and endocrine disorders
- Cardiac glycosides as natural products
- Pharmaceutical analysis of natural products - Practical mini-project
* Clinical therapeutics theme
- The biochemistry of glucose metabolism and fatty acid metabolism
- The management of hypertension
- Angina, acute coronary syndromes, myocardial infarction
- Heart failure
- Cardiac arrhythmias, anti-arrhythmic drugs
- Diabetes types I & II, antidiabetic drugs, insulin delivery
- Thyroid & pituitary diseases
- Clinical decision-making in cardiovascular and endocrine diseases.
* Simulation and practice-based learning in cardiology
* Interprofessional solutions to cardiovascular risk management.
Further information on programme availabilityProgramme availability:

PA20321 is a Designated Essential Unit on the following programmes:

Department of Pharmacy & Pharmacology
  • USPA-AFM03 : MPharm(Hons) Pharmacy (Year 2)
  • USPA-AKM03 : MPharm(Hons) Pharmacy with integrated pre-registration year (Year 2)

Notes: